Metallotherapeutics, or metal-based small molecule therapeutics, are unquestionably some of the most effective anticancer agents available. Despite significant advances in biologic and gene therapies, cisplatin, carboplatin and oxaliplatin continue to be included in the WHO Model List of Essential Medicines, and even today a majority of cancer patients receive a metallotherapeutic at some point in the course of their treatment.
Cisplatin, or (SP-4-2)-diamminedichloridoplatinum(II), arguably the first metallotherapeutic, remains one of the most potent and widely used anticancer drugs, with proven utility in the treatment of testicular, ovarian, head and neck, bladder, lung, and cervical cancer, as well as melanoma and lymphomas. Cisplatin has a multimodal mechanism-of-action, with its primary mechanism involving generation of DNA lesions by interacting with purine bases on DNA followed by activation of several signal transduction pathways which finally lead to apoptosis. Unlike targeted therapies, which are easily evaded through pathway redundancy and resistance mechanisms, this multimodal mechanism-of-action gives cisplatin unmatched breadth of utility across indications and combinations.
Like cisplatin, Bold Therapeutics' BOLD-100 also has a unique multimodal mechanism-of-action whose therapeutic potential is becoming increasingly evident. Like cisplatin, BOLD-100 causes DNA damage and cell cycle arrest -- but it also alters the unfolded protein response (UPR) through selective GRP78 inhibition, a mechanism that appears difficult to evade and particularly effective against heavily mutated or resistant cancer cell lines. As a result, extensive preclinical and, more recently, clinical data suggests that BOLD-100 could enhance the effectiveness of a wide range of existing cancer therapies and significantly improve patient outcomes. BOLD-100 has already received Orphan Drug Designations (ODDs) in gastric and pancreatic cancer and expects to receive a Breakthrough Therapy Designation (BTD) in colorectal cancer and potentially other gastrointestinal cancer indications in the near future.
Realizing the untapped potential of metallotherapeutics and leveraging unparalleled development and manufacturing expertise in metallotherapeutics, Bold Therapeutics is focused on discovering and developing the next generation of metallotherapeutics with novel mechanisms-of-action, broad therapeutic potential, high potency, and low systemic toxicity.
BOLD-100 is the most clinically advanced ruthenium-based therapeutic currently in development. BOLD-100 is currently being studied in a global Phase 2 trial with 6 sites in Canada, 2 in the U.S. and 5 in South Korea, in combination with FOLFOX for the treatment of advanced gastrointestinal (bile duct, colon, gastric, and pancreatic) cancers (NCT04421820).
In April 2023, efficacy data from the Phase 2 study in advanced colorectal cancer was presented at the American Association for Cancer Research (AACR) 2023, showing a clinically significant improvement over standard of care. For patients in the 3rd line and beyond advanced colorectal cancer group (n=17), results showed a positive median Progression-Free Survival (PFS) of 4.7 months, Overall Survival (OS) of 9.8 months, and Overall Response Rate (ORR) of 13%. These results compare favorably to Standard of Care data (median PFS: 2.0 months; median OS: 7.1 months, ORR: 1.5%). AACR 2023 poster can be viewed here.
Preliminary efficacy data from the Phase 2 study on advanced gastric and biliary tract cancer cohorts was presented in June 2023 at the American Society of Clinical Oncology (ASCO) annual meeting. The results suggest an improvement over the standard of care, demonstrating clinical significance. Among patients in the advanced gastric cancer group (n=13), median Progression-Free Survival (PFS) was 5.5 months, median OS 15 months, Overall Response Rate (ORR) of 22%, and disease control rate (DCR) 89%. These findings were notably better than the Standard of Care data, which showed a median PFS of 4.6 months, median OS of 7.1 months, and ORR of 40%. Similarly, for patients in the advanced biliary tract cancer group (n=22), the study demonstrated a positive median PFS of 5.0 months, OS of 7.3 months, ORR of 6%, and DCR 83%. These results compare favorably to Standard of Care data, where benchmarks are a median PFS of 4.0 months, median OS of 6.2 months, ORR of 5% and DCR 33%. ASCO 2023 poster can be viewed here.
BOLD-100 has received Orphan Drug Designations (ODDs) from the FDA in both gastric and pancreatic cancers, and BOLD-100 is expected to receive breakthrough therapy designations (BTDs) in 2023 in colorectal cancer and potentially other indications.
Please visit clinicaltrials.gov for more information for more information.
BOLD-100 is an anticancer agent being developed in combination with standard-of-care therapies, to improve patient outcomes in difficult to treat cancers. Most current treatment strategies for advanced cancers are either effective in only some patient populations or have high relapse rates. BOLD-100 is designed to be used in combination with these treatments to improve patient outcomes. In preclinical studies, BOLD-100 enhances a wide range of therapies, including standard of care agents like chemotherapies and targeted agents, but also novel drugs currently in development like ATR inhibitors.
BOLD-100 has a unique, multimodal mechanism-of-action that selectively kills cancerous cells. Specifically, BOLD-100 alters the unfolded protein response (UPR) through selective GRP78 inhibition, leading to endoplasmic reticulum stress, activation of the unfolded protein response, and cellular death via apoptosis. Additionally, cancer cells utilize this pathway to become resistant to standard of care therapies - by targeting this pathway, BOLD-100 is able to overcome this resistance, improving outcomes in both sensitive and resistant cancers.
BOLD-100 also induces reactive oxygen species (ROS) which causes DNA damage and cell cycle arrest. DNA damaging agents are a mainstay of cancer therapy - by also activating this pathway, BOLD-100 can potentiate the effect of current cancer therapies, demonstrating the unique potential of combinational strategies with BOLD-100 to potentiate efficacy while overcoming resistance.
Bold Therapeutics is developing a robust pipeline of novel metallotherapeutics. We have developed an innovative, best-in-class screening platform to identify metallotherapeutics with high anticancer activity and low toxicity. Leveraging the unique properties of metallotherapeutics, this screening program is specifically designed to identify compounds with novel anticancer mechanisms. Working with an extensive global network of leading academic chemists, Bold Therapeutic has access to the most innovate metallotherapeutic compounds in development. Research and development activities for pipeline expansion with BOLD-200 and BOLD-300 are ongoing while screening continues in the search for new and interesting metallotherapeutics. We encourage potential collaborators to connect with us here.
Bold Therapeutics is working with a leading team of international partners, clinicians and collaborators to develop BOLD-100. We believe collaborations and partnerships are the key to scientific discovery and advancement. Connect with us if you’re interested in collaborating with us to explore the potential of BOLD-100.Connect With Us
BOLD-100 and its precursor molecules’ (KP1339, NKP-1339, IT-139) clinical scientific and clinical advancements have been presented and published in dozens of peer-reviewed forums.
A full list of publications is available here.
Select papers / posters:
Spratlin JL, O’Kane G, Goodwin RA, et al. BOLD-100-001 (TRIO039): A phase 1b dose-escalation study of BOLD-100 in combination with FOLFOX chemotherapy in patients with advanced gastrointestinal solid cancers: Interim safety, tolerability, and efficacy. ASCO 2022 Abstract. View
Bakewell S, Conde I, Fallah Y, et al. Inhibition of DNA Repair Pathways and Induction of ROS Are Potential Mechanisms of Action of the Small Molecule Inhibitor BOLD-100 in Breast Cancer. Cancers (Basel). 2020 Sep 16;12(9):2647. View
Neuditschko B, Legin AA, Baier D, et al. Interaction with Ribosomal Proteins Accompanies Stress Induction of the Anticancer Metallodrug BOLD-100/KP1339 in the Endoplasmic Reticulum. Angew Chem Int Ed Engl. 2021 Mar 1;60(10):5063-5068. View
Burris HA, Bakewell S, Bendell JC, et al. Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort. ESMO Open. 2017;1(6):e000154. Published 2017 Feb 23. View
Bakewell SJ, Rangel DF, Ha DP, et al. Suppression of stress induction of the 78-kilodalton glucose regulated protein (GRP78) in cancer by IT-139, an anti-tumor ruthenium small molecule inhibitor. Oncotarget. 2018;9(51):29698–29714. Published 2018 Jul 3. View
Lizardo MM, Morrow JJ, Miller TE, et al. Upregulation of Glucose-Regulated Protein 78 in Metastatic Cancer Cells Is Necessary for Lung Metastasis Progression. Neoplasia. 2016;18(11):699–710. View
Heffeter P, Atil B, Kryeziu K, et al. The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. Eur J Cancer. 2013;49(15):3366–3375. View
Gifford JB, Huang W, Zeleniak AE, et al. Expression of GRP78, Master Regulator of the Unfolded Protein Response, Increases Chemoresistance in Pancreatic Ductal Adenocarcinoma. Mol Cancer Ther. 2016;15(5):1043–1052. View